#USPSTF guidelines now recommend #coloncancer screenings starting at age 45. Dr. Robin Mendelsohn explains where MSK’s Center for Young Onset Colorectal and Gastrointestinal Cancer comes in. bit.ly/3wveWK4

All smiles this morning during Academic Tuesday as we virtually take our MD Anderson Cancer Center Hematology/Oncology Fellowship Class Photo 📸

First in-person conference with my co-fellows #COA2022 Jin Guo, MD Igryl Cordero-Hernandez, MD

Grateful for a week of networking and learning more about community oncology #COA2022 Community Oncology Igryl Cordero-Hernandez, MD @esinghimd

So excited for our future in Oncology! 🩺 #COA2022

Such a surreal feeling to reflect on my hematology/oncology fellowship experience thus far during my PGY-6 talk last week. Here are some of the key “take-aways” that I’ve learned during my time in training, a 🧵:

Biomarker analysis from CALGB40601 & PAMELA trials show that when #TILs and #RNAseq immune signatures are available, prognostic & predictive value of immune signatures appears best. ja.ma/3vDWaSs #BCSM

📣 💥 Please mark your calendars to join us Tues Feb 7 — we have an all-star line-up of experts to discuss MPN for Heme Reports! Ruben A. Mesa, MD Angela Fleischman Gaby Hobbs Aaron Gerds MD, MS Raajit Rampal, M.D.Ph.D. Dr. Uma Borate: Associate Professor Andrew Kuykendall MD Stephen Oh #TwitterSpaces #MPNSM Sanam Loghavi, MD صنم لغوی 🔬🧬

Adjuvant ALK inhibitor alectinib significantly improves DFS for resected #NSCLC! Phase III ALINA trial meets primary endpoint, per ⁦Roche⁩ press release. ⁦OncoAlert⁩ ⁦ASCO⁩ ⁦ESMO - Eur. Oncology⁩ ⁦IASLC⁩ ⁩ ⁦Oncology Brothers⁩ gene.com/media/press-re…

🚀 First day as an Oncologist-Hematologist at NY Cancer Blood Specialists in Long Island. Thrilled to give back to my hometown, helping those in the fight against cancer. Let's make a difference together! 💪 NYCancerSpecialists OneOncology #CommunityOncology #EndCancer

🚨CheckMate-77T: Perioperative nivolumab with chemotherapy significantly improves EFS for patients with resectable NSCLC #lcsm OncoAlert

“In a 🌍 where physicians are already burdened w/ mandatory health stream modules, electronic documentation, complex billing necessities, & the ⬆️ obligation of obtaining prior authorization for almost every test, ABIM MOC adds an extra burden.” Dipesh Uprety MD FACP H. Jack West, MD, FASCO

nature.com/articles/s4159… Sumanta K. Pal, MD, FASCO Sia Daneshmand, M.D. Ronac Mamtani Horowitz Lab @Icahn School of Medicine Mount Sinai Reza Mehrazin, MD Bhardwaj Lab Dr. John Sfakianos Neeraj Agarwal, MD, FASCO Hoosier Cancer Icahn School of Medicine at Mount Sinai Lipschultz Precision Immunology Institute

THIS!! Equitable access in the crossover arm matters for our patients!! 👏🏽 #ALINA #lcsm #ESMO23

Agree fully with Jonathan Rosenberg MD huge & transformative progress! ESMO - Eur. Oncology #ESMO23 OncoAlert

PSMAfore finally out! PSMA Lutetium pre chemo showing clinical benefit to patients with #mCRPC showing delayed progression and better #qol . However, 84% crossover and no signal of OS benefit without adjustment for crossover means later is just as good as earlier for OS.

#ESMO23 Axel S. Merseburger presents impactful data👉 in mCSPC #prostatecancer from the ph3 Titan trial (ADT+Apalutamide): PSA <|=0.02 ng/ml at 3 mo associated with 75% ⬇️in risk of death.👇OncoAlert UroToday.com Advanced Prostate Cancer Consensus Conference PCF Science @uromigos Link👉 rb.gy/480fc

Clonal hematopoiesis and the development of secondary PTCL in the context of CAR T-cell therapy. The authors provide evidence that clonal hematopoiesis in the apheresis product and the final CAR T-cell product contributed to lymphomagenesis #lysm nejm.org/doi/full/10.10…

Quick revision: Comparison between Monarch E and NATALEE

#ESMO2025 Berlin is SOON here 🇩🇪 🚀 My #Top10 for #NSCLC ESMO - Eur. Oncology Many important trials and potentially practice-changing 👇🏽🫁 🌍 Follow the global dream team: #OncoAlertAF OncoAlert